MX343671B - Metodos de tratamiento de cancer de vejiga. - Google Patents
Metodos de tratamiento de cancer de vejiga.Info
- Publication number
- MX343671B MX343671B MX2012013909A MX2012013909A MX343671B MX 343671 B MX343671 B MX 343671B MX 2012013909 A MX2012013909 A MX 2012013909A MX 2012013909 A MX2012013909 A MX 2012013909A MX 343671 B MX343671 B MX 343671B
- Authority
- MX
- Mexico
- Prior art keywords
- bladder cancer
- methods
- treating bladder
- treating
- taxane
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
La presente invención provee métodos y composiciones para tratamiento de cáncer de vejiga, incluyendo cáncer de vejiga metastático y cáncer de vejiga no musculo invasivo al administrar una composición que comprende nanopartículas que comprenden un taxano y una albumina.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39680010P | 2010-06-02 | 2010-06-02 | |
US201161449513P | 2011-03-04 | 2011-03-04 | |
PCT/US2011/037449 WO2011153009A1 (en) | 2010-06-02 | 2011-05-20 | Methods of treating bladder cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2012013909A MX2012013909A (es) | 2013-02-21 |
MX343671B true MX343671B (es) | 2016-11-16 |
Family
ID=45067028
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2012013909A MX343671B (es) | 2010-06-02 | 2011-05-20 | Metodos de tratamiento de cancer de vejiga. |
Country Status (20)
Country | Link |
---|---|
US (2) | US20130266659A1 (es) |
EP (1) | EP2575803B1 (es) |
JP (1) | JP2013527232A (es) |
KR (1) | KR20130109025A (es) |
CN (1) | CN103221042B (es) |
AU (1) | AU2011261684B2 (es) |
BR (1) | BR112012030699A2 (es) |
CA (1) | CA2801314A1 (es) |
CO (1) | CO6620019A2 (es) |
CR (1) | CR20120619A (es) |
ES (1) | ES2639038T3 (es) |
MX (1) | MX343671B (es) |
MY (1) | MY188911A (es) |
NI (1) | NI201200175A (es) |
NZ (2) | NZ708506A (es) |
PH (1) | PH12016502066A1 (es) |
RU (1) | RU2621640C2 (es) |
SG (1) | SG186109A1 (es) |
WO (1) | WO2011153009A1 (es) |
ZA (1) | ZA201208815B (es) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
CN104587479A (zh) | 2002-12-09 | 2015-05-06 | 阿布拉西斯生物科学有限责任公司 | 组合物和传递药剂的方法 |
ATE531365T1 (de) | 2005-02-18 | 2011-11-15 | Abraxis Bioscience Llc | Kombinationen und modi zur verabreichung therapeutischer mittel und kombinationstherapie |
US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
DK3311805T3 (da) * | 2005-08-31 | 2020-04-14 | Abraxis Bioscience Llc | Sammensætninger, der omfatter svært vandopløselige farmaceutiske midler og antimikrobielle midler |
CA2672618C (en) | 2006-12-14 | 2021-03-02 | Abraxis Bioscience, Llc | Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane |
SI2131821T1 (sl) * | 2007-03-07 | 2018-11-30 | Abraxis Bioscience, Llc | Nanodelci, ki zajemajo rapamicin in albumin kot sredstvo proti raku |
EP2155188B1 (en) | 2007-06-01 | 2013-10-09 | Abraxis BioScience, LLC | Methods and compositions for treating recurrent cancer |
RU2559570C2 (ru) | 2009-04-15 | 2015-08-10 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Композиции без приона на основе наночастиц и способы их получения |
AU2011230512B2 (en) | 2010-03-26 | 2016-09-15 | Abraxis Bioscience, Llc | Methods of treatment of hepatocellular carcinoma |
PL2552415T3 (pl) | 2010-03-29 | 2017-03-31 | Abraxis Bioscience, Llc | Sposoby leczenia nowotworu |
CN105147613A (zh) | 2010-03-29 | 2015-12-16 | 阿布拉科斯生物科学有限公司 | 增强药物递送和治疗剂有效性的方法 |
KR102447139B1 (ko) | 2010-05-14 | 2022-09-23 | 더 제너럴 하스피톨 코포레이션 | 종양 특이적 신생항원을 확인하는 조성물 및 방법 |
MY162903A (en) | 2010-06-04 | 2017-07-31 | Abraxis Bioscience Llc | Methods of treatment of pancreatic cancer |
MY166014A (en) * | 2010-06-07 | 2018-05-21 | Abraxis Bioscience Llc | Combination therapy methods for treating proliferative diseases |
KR20200051841A (ko) | 2011-04-28 | 2020-05-13 | 아브락시스 바이오사이언스, 엘엘씨 | 나노입자 조성물의 혈관내 전달 및 그의 용도 |
BR112014014323A2 (pt) | 2011-12-14 | 2017-06-13 | Abraxis Bioscience Llc | uso de excipientes poliméricos para liofilização ou congelamento de partículas |
DK177379B1 (en) * | 2012-03-29 | 2013-02-25 | Entomopharm Aps | Insect-based model to study the effect and integrity of nanoparticles on blood-brain barrier function |
US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
US20140199404A1 (en) * | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on level of a nucleoside transporter |
US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
NZ630392A (en) | 2013-03-12 | 2016-10-28 | Abraxis Bioscience Llc | Methods of treating lung cancer |
NZ630367A (en) * | 2013-03-13 | 2017-02-24 | Abraxis Bioscience Llc | Methods of treatment of pediatric solid tumor |
JP6309610B2 (ja) | 2013-03-14 | 2018-04-11 | アブラクシス バイオサイエンス, エルエルシー | 膀胱がんを処置する方法 |
WO2015077717A1 (en) | 2013-11-25 | 2015-05-28 | The Broad Institute Inc. | Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status |
WO2015085147A1 (en) | 2013-12-05 | 2015-06-11 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
KR20160101073A (ko) | 2013-12-20 | 2016-08-24 | 더 브로드 인스티튜트, 인코퍼레이티드 | 신생항원 백신과의 병용 요법 |
WO2015018380A2 (en) * | 2014-07-03 | 2015-02-12 | Cspc Zhongqi Pharmaceutical Technology(Shijiazhuang)Co., Ltd. | Therapeutic nanoparticles and the preparation methods thereof |
EP3234193B1 (en) | 2014-12-19 | 2020-07-15 | Massachusetts Institute of Technology | Molecular biomarkers for cancer immunotherapy |
US10993997B2 (en) | 2014-12-19 | 2021-05-04 | The Broad Institute, Inc. | Methods for profiling the t cell repertoire |
US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
CN116196401A (zh) | 2015-05-20 | 2023-06-02 | 博德研究所 | 共有的新抗原 |
US11291646B2 (en) | 2015-06-04 | 2022-04-05 | Crititech, Inc. | Nozzle assembly and methods for use |
US20180177771A1 (en) * | 2015-06-29 | 2018-06-28 | Abraxis Bioscience, Llc | Biomarkers for nanoparticle compositions |
DK3313401T3 (da) | 2015-06-29 | 2021-11-15 | Abraxis Bioscience Llc | Nanopartikler omfattende sirolimus og albumin til anvendelse i behandling af epithelioide celletumorer |
EP3328380A4 (en) * | 2015-07-31 | 2019-07-24 | Pharmacyclics LLC | INHIBITOR COMBINATIONS OF BRUTON TYROSINE KINASE AND USES THEREOF |
CA3018989A1 (en) | 2016-04-04 | 2017-10-12 | Crititech, Inc. | Methods for solid tumor treatment |
WO2017193098A1 (en) * | 2016-05-06 | 2017-11-09 | Taris Biomedical Llc | Method of treating lower tract urothelial cancer |
EP3574116A1 (en) | 2017-01-24 | 2019-12-04 | The Broad Institute, Inc. | Compositions and methods for detecting a mutant variant of a polynucleotide |
CA3063420A1 (en) | 2017-06-09 | 2018-12-13 | Crititech, Inc. | Treatment of epithelial cysts by intracystic injection of antineoplastic particles |
SG10201913400QA (en) | 2017-06-14 | 2020-03-30 | Crititech Inc | Methods for treating lung disorders |
BR112020000832A2 (pt) | 2017-07-25 | 2020-07-21 | Taris Biomedical Llc | métodos para tratar metástase tumoral |
JP2020536052A (ja) | 2017-10-03 | 2020-12-10 | クリティテック・インコーポレイテッド | 癌の治療のための免疫療法剤の全身送達と組み合わせた抗腫瘍粒子の局所送達 |
CN111787926A (zh) | 2017-11-08 | 2020-10-16 | 塔里斯生物医药公司 | 使用吉西他滨对膀胱癌进行治疗和维持疗法的方法 |
WO2019126186A1 (en) | 2017-12-18 | 2019-06-27 | Neon Therapeutics, Inc. | Neoantigens and uses thereof |
WO2019136187A1 (en) * | 2018-01-05 | 2019-07-11 | Crititech, Inc. | Treatment of bladder cancer by local administration of taxane particles |
KR20200135410A (ko) | 2018-03-20 | 2020-12-02 | 아브락시스 바이오사이언스, 엘엘씨 | mTOR 억제제 및 알부민의 나노입자의 투여를 통한 중추 신경계 장애의 치료 방법 |
WO2020072090A1 (en) * | 2018-10-03 | 2020-04-09 | Crititech, Inc. | Use of antineoplastic agents to stimulate the immune system for production of tertiary lymphoid structures (tls) |
KR20220106758A (ko) | 2019-10-28 | 2022-07-29 | 아브락시스 바이오사이언스, 엘엘씨 | 알부민 및 라파마이신의 제약 조성물 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
US5916596A (en) | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
DK1155689T3 (da) * | 1993-07-19 | 2006-11-20 | Angiotech Pharm Inc | Antiangiogene stents og fremgangsmåder til fremstilling heraf |
GB9811598D0 (en) * | 1998-05-30 | 1998-07-29 | Imp College Innovations Ltd | Diagnosis and treatment of cancer |
RU2361615C2 (ru) * | 2002-12-09 | 2009-07-20 | Абраксис Байосайенс, Ллс. | Композиции и способы доставки фармакологических агентов |
CN104587479A (zh) | 2002-12-09 | 2015-05-06 | 阿布拉西斯生物科学有限责任公司 | 组合物和传递药剂的方法 |
AU2006249235B2 (en) * | 2004-05-14 | 2010-11-11 | Abraxis Bioscience, Llc | Sparc and methods of use thereof |
ATE531365T1 (de) * | 2005-02-18 | 2011-11-15 | Abraxis Bioscience Llc | Kombinationen und modi zur verabreichung therapeutischer mittel und kombinationstherapie |
BRPI0615292A8 (pt) | 2005-08-31 | 2018-03-06 | Abraxis Bioscience Llc | composições e métodos para preparação de fármacos de má solubilidade em água com estabilidade aumentada |
JP5641927B2 (ja) * | 2007-04-13 | 2014-12-17 | アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー | Sparc及びその使用方法 |
CA2686736A1 (en) | 2007-05-03 | 2008-11-13 | Abraxis Bioscience, Llc | Nanoparticle compositions comprising rapamycin for treating pulmonary hypertension |
EP2367425B1 (en) * | 2008-12-11 | 2018-02-28 | Abraxis BioScience, LLC | Combination therapy including a taxane and a further therapeutic agent |
RU2561055C2 (ru) * | 2009-08-25 | 2015-08-20 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Комбинированная терапия композициями наночастиц таксана и ингибиторами хэджхог |
-
2011
- 2011-05-20 KR KR1020127034199A patent/KR20130109025A/ko not_active Application Discontinuation
- 2011-05-20 NZ NZ708506A patent/NZ708506A/en unknown
- 2011-05-20 MY MYPI2012005167A patent/MY188911A/en unknown
- 2011-05-20 RU RU2012157805A patent/RU2621640C2/ru active
- 2011-05-20 AU AU2011261684A patent/AU2011261684B2/en active Active
- 2011-05-20 BR BR112012030699A patent/BR112012030699A2/pt not_active Application Discontinuation
- 2011-05-20 NZ NZ604029A patent/NZ604029A/en unknown
- 2011-05-20 SG SG2012088019A patent/SG186109A1/en unknown
- 2011-05-20 WO PCT/US2011/037449 patent/WO2011153009A1/en active Application Filing
- 2011-05-20 CA CA2801314A patent/CA2801314A1/en not_active Abandoned
- 2011-05-20 CN CN201180038029.3A patent/CN103221042B/zh active Active
- 2011-05-20 ES ES11790192.6T patent/ES2639038T3/es active Active
- 2011-05-20 JP JP2013513207A patent/JP2013527232A/ja active Pending
- 2011-05-20 MX MX2012013909A patent/MX343671B/es active IP Right Grant
- 2011-05-20 EP EP11790192.6A patent/EP2575803B1/en not_active Revoked
- 2011-05-20 US US13/701,003 patent/US20130266659A1/en not_active Abandoned
-
2012
- 2012-11-22 ZA ZA2012/08815A patent/ZA201208815B/en unknown
- 2012-11-30 NI NI201200175A patent/NI201200175A/es unknown
- 2012-12-10 CR CR20120619A patent/CR20120619A/es unknown
- 2012-12-28 CO CO12236221A patent/CO6620019A2/es unknown
-
2013
- 2013-03-01 US US13/782,984 patent/US20140056986A1/en not_active Abandoned
-
2016
- 2016-10-18 PH PH12016502066A patent/PH12016502066A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
RU2012157805A (ru) | 2014-07-20 |
EP2575803A1 (en) | 2013-04-10 |
ZA201208815B (en) | 2014-01-29 |
SG186109A1 (en) | 2013-01-30 |
CN103221042A (zh) | 2013-07-24 |
MX2012013909A (es) | 2013-02-21 |
EP2575803A4 (en) | 2014-01-01 |
BR112012030699A2 (pt) | 2016-09-13 |
NI201200175A (es) | 2013-05-13 |
WO2011153009A1 (en) | 2011-12-08 |
MY188911A (en) | 2022-01-13 |
KR20130109025A (ko) | 2013-10-07 |
PH12016502066A1 (en) | 2019-02-04 |
RU2621640C2 (ru) | 2017-06-06 |
JP2013527232A (ja) | 2013-06-27 |
US20130266659A1 (en) | 2013-10-10 |
EP2575803B1 (en) | 2017-07-26 |
CR20120619A (es) | 2014-03-21 |
CN103221042B (zh) | 2016-02-10 |
NZ708506A (en) | 2016-08-26 |
US20140056986A1 (en) | 2014-02-27 |
AU2011261684B2 (en) | 2016-09-15 |
CA2801314A1 (en) | 2011-12-08 |
NZ604029A (en) | 2015-07-31 |
CO6620019A2 (es) | 2013-02-15 |
AU2011261684A1 (en) | 2013-01-10 |
ES2639038T3 (es) | 2017-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12016502066A1 (en) | Methods of treating bladder cancer | |
MX2015011753A (es) | Metodos para tratar cancer de vegija. | |
PH12019501393A1 (en) | Afucosylated anti-fgfr2iiib antibodies | |
MX364637B (es) | Platino y nanopartículas que incluyen placlitaxel/albúmina para usarse en el trartamiento de nsclc. | |
MX2015011783A (es) | Metodos para tratar tumores solidos pediatricos. | |
MX346861B (es) | Metodos de tratamiento de carcinoma hepato celular. | |
MX360404B (es) | Compuestos para inhibir la proliferacion celular en canceres transmitidos por egfr. | |
MX2015010312A (es) | Metodos para tratamiento del melanoma. | |
MX2015008889A (es) | Metodo para tratar cancer con base en el estado de la mutacion k-ras. | |
NZ707086A (en) | Anti-cd40 antibodies and methods of use | |
MX2015011752A (es) | Metodos para tratar cancer de pulmon. | |
MX347225B (es) | Metodos de tratamiento contra el cancer pancreatico. | |
TW201611831A (en) | Novel antitumoral use of CABAZITAXEL | |
MX2014012477A (es) | Inhibidores pirrolopirazona de tanquirasa. | |
MY157341A (en) | Methods and compositions for treating lung cancer | |
PH12015501088A1 (en) | Dimeric compounds | |
AU2018253600A1 (en) | Dosage forms and therapeutic uses of l-4-chlorokynurenine | |
EP4023243A3 (en) | Compositions and methods for treating celiac sprue disease | |
TN2013000333A1 (en) | Combinations comprising macitentan for the treatment of glioblastoma multiforme | |
MX2013014488A (es) | Metodos y composiciones para tratar el cancer cerebral. | |
IN2014DN08477A (es) | ||
WO2012158776A3 (en) | Combination therapy for treatment of cancer | |
WO2013070933A3 (en) | Compositions and methods for the treatment of prostate carcinoma | |
WO2013013238A3 (en) | Compounds and related compositions and methods of use | |
TN2012000552A1 (en) | An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |